The latest monthly drug alert released by Central Drugs Standard Control Organisation has once again brought this uncomfortable reality into focus, declaring a large number of medicines as “Not of Standard Quality”, along with the detection of spurious drugs circulating under false identities.

For December, regulators tested hundreds of samples across the country, drawn from manufacturing units, supply chains, and market shelves. The results were shocking. A total of 167 drug samples failed to meet prescribed quality benchmarks. Of these, 74 were identified by central laboratories and 93 by state-level testing facilities. In addition, several samples were flagged as spurious, manufactured by unauthorised entities while misusing brand names that legally belong to other companies. Each number in this list represents more than a regulatory statistic. It represents a patient who may have consumed a medicine that did not perform as promised.

The term “Not of Standard Quality” may sound mild to the lay reader, but within pharmaceutical regulation, it carries serious weight. A drug is labelled NSQ when it fails one or more quality parameters laid down in official standards. These parameters include potency, dissolution, uniformity, stability, and purity. When a medicine falls short, it may contain less active ingredient than stated, degrade faster than expected, or fail to release the drug properly in the body. Such failures may not trigger immediate alarm, yet their clinical impact can be significant, especially for patients managing chronic illnesses, infections, or life-threatening conditions.

Regulators are quick to clarify that an NSQ finding applies only to the specific batch tested and does not automatically condemn all products from the same manufacturer. This distinction is important, yet it does not dilute the seriousness of the issue. For a patient, a batch number is invisible. What matters is whether the pill swallowed today will work as intended. When hundreds of batches fail every year, confidence begins to erode, quietly and cumulatively.

The December alert also reported the identification of spurious drugs from multiple regions, including northern and western parts of the country. These medicines were not merely substandard; they were fraudulent. Manufactured by unauthorised units, they carried brand names that legally belong to established companies, misleading doctors, pharmacists, and patients alike. Spurious drugs strike at the heart of medicine safety because they often bypass quality systems entirely. Their composition may be unknown, inconsistent, or dangerous, and tracing their source is notoriously difficult.

What makes this pattern particularly concerning is its persistence. Month after month, similar alerts are issued, sometimes with higher numbers, sometimes lower, but rarely absent. In an earlier notification, regulators had flagged more than 200 samples as NSQ, with state laboratories accounting for a large share.

India has one of the largest pharmaceutical industries in the world, supplying medicines to domestic patients and to markets across Asia, Africa, Europe, and the Americas. Continuous testing by central and state laboratories is meant to act as an early warning system, identifying problematic batches before harm becomes widespread. Publishing monthly alerts on the public portal signals transparency and a willingness to acknowledge gaps. In that sense, the system is working as designed.

Yet, vigilance alone is not the same as prevention. The repeated appearance of NSQ drugs suggests that quality failures are not isolated accidents. They often stem from issues such as inadequate process control, cost pressures, poor raw material quality, weak internal audits, or inconsistent adherence to Good Manufacturing Practices. For smaller manufacturers operating on thin margins, the temptation to cut corners can be strong. For larger players managing complex supply chains, lapses can occur when oversight becomes fragmented.

The clinical consequences of substandard medicines are often underestimated. A painkiller that contains slightly less active ingredient may seem harmless, but an antibiotic with reduced potency can contribute to treatment failure and antimicrobial resistance. A blood pressure drug that dissolves poorly may leave hypertension uncontrolled, increasing the risk of stroke or heart attack. In oncology, cardiology, and critical care, even small deviations can have disproportionate effects. These are not abstract risks; they play out quietly in clinics and wards across the country.

Doctors, meanwhile, often find themselves caught in the middle. When a patient fails to respond to treatment, the first instinct is to reconsider the diagnosis or escalate therapy. Rarely does the quality of the medicine itself enter the conversation. This blind spot can lead to unnecessary investigations, stronger drugs, higher costs, and avoidable side effects. The assumption that approved medicines meet standards is foundational. When that assumption is shaken, it complicates clinical decision-making in ways that are difficult to quantify.

Pharmacists, too, shoulder an invisible burden. They are the final checkpoint before a medicine reaches the patient, yet they have limited tools to verify quality beyond packaging, labelling, and supplier reputation. A spurious drug designed to mimic a popular brand can be nearly indistinguishable without laboratory analysis. When such products enter the supply chain, responsibility becomes diffuse, and accountability harder to enforce.

The regulatory response to spurious drugs is necessarily stricter. Investigations are initiated, and action is taken under the Drugs and Cosmetics Act and Rules. Raids, prosecutions, and licence cancellations follow when evidence is established. Yet enforcement is often reactive rather than preventive. By the time a spurious drug is identified in a laboratory, it may already have reached multiple markets. Tracing its distribution path requires coordination across states, agencies, and sometimes borders.

India’s pharmaceutical sector has long been described as the “pharmacy of the world,” supplying affordable medicines at scale. This reputation is a strategic asset. Every quality lapse chips away at it, even when confined to a single batch. International regulators, importers, and patients watch these signals closely. Domestically, patients may not read monthly alerts, but stories of failed medicines travel fast, especially in the age of social media.

At the same time, it would be misleading to frame the issue as one of failure alone. The very act of identifying and publishing NSQ data reflects a system that is looking for problems rather than hiding them. Many countries do not publicly disclose such detailed monthly findings. India’s approach creates an opportunity for corrective action, learning, and reform. The challenge lies in translating detection into durable improvement.

Strengthening drug quality requires action at multiple levels. Manufacturers must invest in robust quality assurance systems that go beyond minimum compliance. State drug control departments need adequate staffing, training, and infrastructure to conduct inspections and follow-up effectively. Laboratories must be equipped to test a growing range of complex formulations with speed and accuracy. Data from surveillance should be analysed for patterns, helping regulators identify repeat offenders, high-risk categories, and systemic vulnerabilities.

There is also a role for policy reform. Faster recall mechanisms, stronger penalties for repeat violations, and incentives for quality excellence can shift industry behaviour. Digital tools that track batches through the supply chain could improve traceability, making it harder for spurious products to hide. Public awareness campaigns, targeted at healthcare professionals, can encourage reporting of suspected quality issues, creating a feedback loop from the field to the regulator.

The December alert, with its list of 167 NSQ samples and several spurious drugs is part of an ongoing narrative about medicine quality in a complex, high-volume healthcare system. Each alert is a reminder that regulation is not a one-time seal of approval but a continuous process. Quality is not guaranteed by reputation alone; it must be earned and re-earned with every batch.

As India expands its healthcare ambitions, from universal coverage to advanced therapies, the foundation of trust in medicines becomes even more critical. Sophisticated diagnostics and cutting-edge treatments mean little if the basic building blocks of care are unreliable. Drug quality is not a peripheral issue reserved for regulators and manufacturers. It is central to patient safety, clinical outcomes, and the credibility of the entire healthcare system.

The quiet failure of a medicine is often more dangerous than an obvious one. It does not trigger immediate alarm, yet it shapes outcomes in subtle, cumulative ways. By shining a light on NSQ and spurious drugs, regulators are forcing the system to confront uncomfortable truths. The real test lies in what follows these alerts. Whether they remain routine disclosures, or become catalysts for lasting change, will determine how safe India’s medicines truly are